Omicron-specific vaccines under development at Moderna and the Pfizer-BioNTech partnership will be “little or no better” than currently available boosters, shifting the focus to the next generation of pan-coronavirus shots. https://t.co/3hL31ADEt9— Bloomberg (@business) August 10, 2022
(SocialLY brings you all the latest breaking news, viral trends and information from social media world, including Twitter (X), Instagram and Youtube. The above post is embeded directly from the user's social media account and LatestLY Staff may not have modified or edited the content body. The views and facts appearing in the social media post do not reflect the opinions of LatestLY, also LatestLY does not assume any responsibility or liability for the same.)